Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV000164697 | SCV000215365 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-28 | criteria provided, single submitter | clinical testing | The p.Q1998P variant (also known as c.5993A>C), located in coding exon 10 of the BRCA2 gene, results from an A to C substitution at nucleotide position 5993. The glutamine at codon 1998 is replaced by proline, an amino acid with similar properties. This alteration has been reported with a carrier frequency of 0 in 7051 unselected breast cancer patients and 0.00018 in 11241 female controls of Japanese ancestry (Momozawa Y et al. Nat Commun, 2018 10;9:4083). This amino acid position is well conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000758916 | SCV000887862 | uncertain significance | not provided | 2018-05-30 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002515145 | SCV003472654 | uncertain significance | Hereditary breast ovarian cancer syndrome | 2022-07-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt BRCA2 protein function. ClinVar contains an entry for this variant (Variation ID: 185301). This variant has not been reported in the literature in individuals affected with BRCA2-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces glutamine, which is neutral and polar, with proline, which is neutral and non-polar, at codon 1998 of the BRCA2 protein (p.Gln1998Pro). |
University of Washington Department of Laboratory Medicine, |
RCV000164697 | SCV003850841 | likely benign | Hereditary cancer-predisposing syndrome | 2023-03-23 | criteria provided, single submitter | curation | Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673). |